Evan Bernath

Investment Associate

Anita Watkins

Managing Director

21 past transactions

410 Medical

Series B in 2025
410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

G.I. Windows

Series B in 2024
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Synaptrix

Series A in 2024
Synaptrix specializes in developing innovative, non-opioid pain management solutions. The company focuses on creating medical devices that employ neuromodulation technology, using electrical or chemical stimulation to alleviate postoperative pain without compromising motor function or touch. This approach aims to provide healthcare professionals with effective, long-lasting alternatives to opioids, promoting rehabilitation and reducing the need for these medications.

Arrivo BioVentures

Series B in 2023
Founded in 2015, Arrivo BioVentures specializes in developing biologics and small molecules to enhance patient care. The company focuses on efficient clinical programs, coordinating with regulatory bodies early on to expedite drug approvals.

Censinet

Venture Round in 2023
Censinet, Inc. is a cloud-based platform provider focused on managing third-party risk for healthcare organizations. Established in 2017 and headquartered in Winchester, Massachusetts, Censinet's platform facilitates real-time assessments of risks associated with vendors and third-party providers. By connecting healthcare providers with their vendors, the platform streamlines workflows, automates manual processes, and eliminates reliance on inefficient spreadsheets. Censinet delivers continuous insights into the evolving risk profiles of vendors, enabling healthcare companies to effectively address challenges in managing third-party risks while enhancing overall cybersecurity measures.

Vergent Bioscience

Series B in 2022
Vergent Bioscience, Inc. is a company focused on improving cancer surgery outcomes through the development of molecularly-targeted imaging probes. Founded in 2013 and based in Minneapolis, Minnesota, Vergent manufactures a tumor-targeted fluorescent probe, known as VGT-309, which binds to enzymes overexpressed in various cancerous tissues. Upon injection prior to surgery, this probe activates a bright fluorescing dye that illuminates cancerous cells, allowing surgeons to differentiate between malignant and normal tissue with enhanced clarity. By providing a clear visual guide during surgical procedures, Vergent's technology aims to facilitate the complete removal of tumors and reduce the likelihood of residual cancer, thereby addressing a critical need in the surgical oncology field. The company's innovative approach is applicable to multiple cancer types, including lung, breast, ovarian, colorectal, and brain cancers, and is designed to support advanced visualization in various surgical techniques, including open, laparoscopic, and robotic surgeries.

Pryon

Funding Round in 2021
Pryon is an artificial intelligence company specializing in enterprise knowledge management. Founded by Igor Jablokov in 2017, the company develops a natural language processing platform that transforms unstructured data into productive experiences, increasing efficiency with high accuracy and speed.

BioStable

Series C in 2020
BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Bardy Diagnostics

Series B in 2019
Founded in 2013, Bardy Diagnostics specializes in developing advanced cardiac monitoring devices. Its flagship product is the Carnation Ambulatory Monitor (CAM), a discreet and comfortable patch monitor designed to capture clear P-wave signals for accurate arrhythmia detection. The company also offers BDxCONNECT, a patient management system that aids clinical decision-making by providing easy access to CAM reports.

Phynd Technologies

Series B in 2019
Phynd Technologies Inc. is a healthcare technology company based in Dallas, Texas, founded in 2012. It offers a Software-as-a-Service data management platform designed to simplify the management of healthcare provider data for organizations across the United States. The platform, known as Unified Provider Management (UPM), serves as a central hub for managing critical provider information, including billing addresses, communication preferences, licensing details, and exclusionary lists. Additionally, the platform includes tools for provider enrollment, management, outreach, and search, ensuring that healthcare systems can efficiently maintain and utilize provider data across electronic health records, marketing, and claims systems. Phynd Technologies has gained traction in the healthcare industry, with over 350 hospitals and more than 20,000 locations utilizing its solutions to enhance financial outcomes and clinical results while minimizing compliance risks. The company also offers verification services to further support its clients.

Gauss Surgical

Series C in 2018
Gauss Surgical, Inc. is a medical technology company that specializes in real-time blood monitoring solutions to enhance patient outcomes in surgical and obstetric settings. Founded in 2011 and headquartered in Los Altos, California, Gauss Surgical develops the Triton system, which includes various models suited for different medical needs. Triton assists healthcare professionals in monitoring and estimating blood loss during procedures, allowing for timely intervention in cases of hemorrhage. The system offers objective metrics for blood loss, thereby facilitating better clinical decision-making regarding transfusions. Serving the healthcare sector primarily in the United States, Gauss Surgical's products are designed to integrate seamlessly into existing medical practices, using sophisticated algorithms and HIPAA-compliant technology to deliver accurate monitoring in real time.

Emergo Therapeutics

Series A in 2018
Founded in 2016, Emergo Therapeutics is a pharmaceutical company based in Durham, North Carolina. It specializes in developing drugs that modulate inflammatory cytokines to improve immune system functioning, with a focus on treating uncomplicated influenza and other infectious diseases.

Target PharmaSolutions

Series A in 2016
TARGET PharmaSolutions, Inc. specializes in providing real-world data solutions tailored for drug development and commercialization. Founded in 2015 and headquartered in Durham, North Carolina, the company focuses on creating custom datasets and analyses to tackle complex healthcare evidence questions and quality initiatives. It offers a comprehensive health evidence solution that aggregates real-world data from a network of participating sites, in addition to providing bio specimen samples and consulting services. The company's foundation was inspired by the success of HCV-TARGET, a model established in 2011 that demonstrated the efficacy of real-world data in clinical research and regulatory processes. Through its innovative approaches, TARGET PharmaSolutions aims to enhance the drug development process and support evidence-based decision-making in healthcare.

Phononic

Series E in 2016
Phononic designs and manufactures solid-state cooling and heating solutions. Its products include thermoelectric devices and heat pumps used in electronics cooling, refrigeration, and climate control applications. Founded in 2008, the company is headquartered in Durham, North Carolina.

Bluesight

Series C in 2016
Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

Arrivo BioVentures

Series A in 2016
Founded in 2015, Arrivo BioVentures specializes in developing biologics and small molecules to enhance patient care. The company focuses on efficient clinical programs, coordinating with regulatory bodies early on to expedite drug approvals.

Veran Medical Technologies

Venture Round in 2015
Veran Medical Technologies, Inc. is a medical device company specializing in minimally invasive therapeutic devices for interventional oncology. Headquartered in St. Louis, Missouri, the company focuses on developing products that assist physicians in diagnosing diseases and delivering targeted therapies. Its offerings include the SPiNView thoracic navigation system, an electromagnetic device designed for the biopsy of solitary pulmonary nodules, and the ig4 IR System, which aids in performing biopsies and other procedures for the lungs, liver, and kidneys. Additionally, Veran Medical provides various instruments such as the vPad2 tracker device and the SPiNPerc hybrid diagnostic tool. The company's innovative solutions utilize advanced imaging technologies to create dynamic 3D maps of respiratory pathways, enhancing procedural planning and navigation, ultimately helping clinicians to expedite cancer diagnosis and treatment. Founded in 2003, Veran Medical Technologies is committed to improving patient outcomes through precision-guided interventions.

Baebies

Series A in 2015
Baebies develops and manufactures innovative screening equipment for newborn babies. Its flagship product, SEEKER, is an FDA-authorized laboratory solution that simultaneously performs multiple assays using a single dried blood spot specimen. FINDER, another key product, enables near-patient testing in pediatric care. Baebies serves hospitals and public health labs worldwide.

Bluesight

Series B in 2015
Bluesight operates as a healthcare technology company specializing in supply chain optimization for pharmaceuticals. It offers Medication Intelligence solutions that provide real-time analytics across the entire medication lifecycle, enhancing efficiency, reducing risks, and improving patient safety within hospitals. The core product is an inventory management platform that automates pharmacy kit processing and medication tracking, replacing manual processes to increase operational efficiency and medication visibility.

Aerial BioPharma

Venture Round in 2012
Aerial BioPharma is a privately-held biopharmaceutical company based in Morrisville, North Carolina, near Research Triangle Park. Founded in 2011, the company specializes in developing biologics and small molecules targeted at conditions influenced by processes within the central nervous system. Aerial BioPharma's focus includes treatments for narcolepsy and other related conditions, aiming to provide advanced drug therapies for improved healthcare outcomes.

Carta Healthcare

Carta Healthcare provides a software-as-a-service platform that maps the patient journey through hospitals by integrating data from existing information systems. The platform identifies potential bottlenecks weeks in advance and issues alerts about bed shortages and cancellations. It enables hospitals to personalize care by analyzing past patient journeys and using machine learning to predict what the current patient will need and what to expect during treatment. Its clinical data abstraction capabilities automate extraction and processing to improve efficiency, accuracy, and compliance. The solution supports hospitals and research organizations in optimizing patient care, resource allocation, and operational decisions. Founded in 2016 and based in San Mateo, California, Carta Healthcare focuses on turning disparate clinical data into actionable insights to improve care delivery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.